When monitoring patients' factor VIII activity levels during treatment with ReFacto AF, use of the European Pharmacopoeial chromogenic substrate assay is strongly recommended.
Kui ravi ajal ReFacto AF- iga jälgitakse patsiendi VIII faktori taset, on tungivalt soovitatav kasutada Euroopa farmakopöa kromogeensustesti.